Intravenous immunoglobulin in neurological disorders: a mechanistic perspective

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Neurology

• Publication date

  2005-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00415-005-1102-7PMID 15959666
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural antibodies sustain differentiation and maturation of human dendritic cells.

  2004cited by this paper
• Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?

  2004cited by this paper
• Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level.

  2004cited by this paper
• Intravenous immunoglobulin in autoimmune neuromuscular diseases.

  2004influential reference
• Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease.

  2003cited by this paper
• IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity.

  2003cited by this paper
• F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins

  2003cited by this paper
• The role of intravenous immunoglobulin in the treatment of multiple sclerosis.

  2003cited by this paper
• Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin.

  2003cited by this paper
• Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus.

  2003cited by this paper
• Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment.

  2002cited by this paper
• Immunomodulatory action of intravenous immunoglobulin

  2002cited by this paper
• Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

  2001cited by this paper
• High-dose intravenous immune globulin for stiff-person syndrome.

  2001cited by this paper
• Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

  2001cited by this paper
• Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis.

  2000cited by this paper
• Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases.

  1999cited by this paper
• Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg).

  1999cited by this paper
• I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome.

  1999cited by this paper
• IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome

  1999cited by this paper
• Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin G.

  1999cited by this paper
• Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations.

  1998cited by this paper
• High‐Dose Intravenous Immunoglobulin Treatment Activates Complement In Vivo

  1998cited by this paper
• Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

  1998cited by this paper
• Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein

  1998cited by this paper
• Intravenous immunoglobulin treatment in multiple sclerosis Effect on relapses

  1998cited by this paper
• Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway.

  1998cited by this paper
• Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

  1998cited by this paper
• High-avidity autoantibodies to cytokines.

  1998cited by this paper
• Mechanism of Action of Intravenous Immunoglobulin and Therapeutic Considerations in the Treatment of Autoimmune Neurologic Diseases

  1998cited by this paper
• Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases.

  1997cited by this paper
• Intravenous Immune Globulin Therapy for Neurologic Diseases

  1997cited by this paper
• Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin.

  1997cited by this paper
• Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.

  1997cited by this paper
• The Growth Arresting Effect of Human Immunoglobulin for Intravenous Use Is Mediated by Antibodies Recognizing Membrane Glycolipids

  1997cited by this paper
• Intravenous immune globulin affects cytokine production in T lymphocytes and monocytesjmacrophages

  1996cited by this paper
• Intravenous immune globulin: an alternative therapy in steroid‐dependent allergic diseases

  1996cited by this paper
• Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.

  1996cited by this paper
• Selective induction of interleukin‐1 receptor antagonist and interleukin‐8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)

  1995cited by this paper
• Pooled Human IgG Modulates Cytokine Production in Lymphocytes and Monocytes

  1994cited by this paper
• Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg).

  1994cited by this paper
• High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.

  1994cited by this paper
• V Region‐Mediated Selection of Autoreactive Repertoires by Intravenous Immunoglobulin (i.v.Ig)

  1994cited by this paper
• Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis.

  1994cited by this paper
• Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG.

  1993cited by this paper
• Immunologically active proteins in intravenous immunoglobulin.

  1993cited by this paper
• Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)

  1993cited by this paper
• Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations.

  1993cited by this paper
• Prevention of experimental autoimmune uveoretinitis by infusions of human therapeutic intravenous immunoglobulins in rats.

  1993cited by this paper
• Manipulating the immune system with immune globulin.

  1992cited by this paper
• Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain.

  1992cited by this paper
• Polyvalent immunoglobulin for intravenous use interferes with cell proliferationin vitro

  1992cited by this paper
• High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes

  1991cited by this paper
• High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes.

  1991cited by this paper

• A multidisciplinary non-invasive approach to monitor response to intravenous immunoglobulin treatment in neurodegenerative Langerhans cell histiocytosis: a real-world study

  2024cites this paper
• Sepsis-Associated Encephalopathy: from Pathophysiology to Progress in Experimental Studies

  2021cites this paper
• Immunoglobulin for myasthenia gravis

  2020cites this paper
• Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas

  2018cites this paper
• Mechanisms of action of intravenous immunoglobulin in septic encephalopathy

  2017cites this paper
• The Use of Intravenous Immunoglobulins (IVIG) in Immunological Mediated Diseases and Possible Mechanisms of Actions

  2015cites this paper
• Treatment of Spinal Cord Injury with Intravenous Immunoglobulin G: Preliminary Evidence and Future Perspectives

  2014cites this paper
• Intravenous immunoglobulin G improves neurobehavioral and histological outcomes after traumatic brain injury in mice.

  2014cites this paper
• Development, Manufacturing and Characterization of a Highly Purified, Liquid Immunoglobulin G Preparation from Human Plasma

  2014cites this paper
• Intravenous immunoglobulins prevent the breakdown of the blood-brain barrier in experimentally induced sepsis

  2012cites this paper
• [Intravenous immunoglobulin: immunomodulatory key of the immune system].

  2012cites this paper
• Neuroprotection in Sepsis by Complement Inhibition and Immunoglobulin Therapy

  2012cites this paper
• Intravenous immunoglobulin therapy prevents development of autoimmune encephalomyelitis and suppresses activation of matrix metalloproteinases

  2011cites this paper
• Synchronous Activity in Basal Ganglia Circuits

  2010cites this paper
• L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions.

  2010cites this paper
• Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease

  2010cites this paper
• Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen©) stabilized with L‐proline

  2009cites this paper
• Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

  2009cites this paper
• Tratamiento de padecimientos neuromusculares con inmunoglobulina y plasmaféresis

  2009cites this paper
• Basal Ganglia Network Synchronization in Animal Models of Parkinson’s Disease

  2009cites this paper
• Affinity Chromatography–Fractionated and DNA‐Engineered Plasma Proteins

  2009cites this paper
• Immunotherapy of chronic inflammatory demyelinating polyradiculoneuropathy.

  2008cites this paper
• Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy

  2008cites this paper
• Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins

  2008cites this paper
• Immunotherapy of chronic inflammatory demyelinating polyradiculoneuropathy

  2008cites this paper
• Myasthenic crisis: guidelines for prevention and treatment.

  2007cites this paper
• IVIg attenuates T cell-mediated killing of human neurons.

  2006cites this paper
• Immune supplementation and immune modulation with intravenous immunoglobulin.

  2005cites this paper
• Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin

  2005cites this paper